A dual-threat cancer drug takes aim at resistance mechanisms Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.

https://www.drugdiscoverynews.com/a-dual-threat-cancer-drug-takes-aim-at-resistance-mechanisms-16267?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_uFwgsT17e7YliZqlECrwj3aFbL8meTryu8sTGT8OBOY1qjBg2381ZmK22COctScUYJJ1nTGGFYhZlcZPWmgL7T0KMMw&_hsmi=363722390&utm_content=363722390&utm_source=hs_email